Amgen Inc.
Amgen Discloses 2025 Earnings and Non-GAAP Financial Measures
Summary
On February 3, 2026, Amgen Inc. announced its unaudited financial results for the fourth quarter and full year of 2025. The company reported non-GAAP financial measures including earnings per share, operating income, and expenses, adjusted for acquisition-related expenses, restructuring costs, and other items. These non-GAAP measures are provided to enhance understanding of the company's performance and facilitate comparisons with past periods.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement